{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:06:59Z","timestamp":1773252419496,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Thrombotic microangiopathy (TMA) significantly affects kidney graft survival, but its pathophysiology remains poorly understood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>In this multicenter, retrospective, case\u2013control paired study designed to control for donor-associated risks, we assessed the recipients\u2019 risk factors for de novo TMA development and its effects on graft survival. The study group consists of patients with TMA found in case biopsies from 2000 to 2019 (n = 93), and the control group consists of recipients of paired kidney grafts (n = 93). Graft follow-up was initiated at the time of TMA diagnosis and at the same time in the corresponding paired kidney graft.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>The TMA group displayed higher peak panel-reactive antibodies, more frequent retransplantation status, and longer cold ischemia time in univariable analysis. In the multivariable regression model, longer cold ischemia times (odds ratio, 1.18; 95% confidence interval [CI], 1.01-1.39; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.043) and higher peak pretransplant panel-reactive antibodies (odds ratio, 1.03; 95% CI, 1.01-1.06; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.005) were found to be associated with increased risk of de novo TMA. The risk of graft failure was higher in the TMA group at 5 y (hazard ratio [HR], 3.99; 95% CI, 2.04-7.84; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). Concomitant rejection significantly affected graft prognosis at 5 y (HR, 6.36; 95% CI, 2.92-13.87; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). De novo TMA associated with the active antibody-mediated rejection was associated with higher risk of graft failure at 5 y (HR, 3.43; 95% CI, 1.69-6.98; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) compared with other TMA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Longer cold ischemia and allosensitization play a role in de novo TMA development, whereas TMA as a part of active antibody-mediated rejection was associated with the highest risk for premature graft loss.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001239","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T22:46:02Z","timestamp":1634942762000},"page":"e779","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Rejection-associated Phenotype of De Novo Thrombotic Microangiopathy Represents a Risk for Premature Graft Loss"],"prefix":"10.1097","volume":"7","author":[{"given":"Vojtech","family":"Petr","sequence":"first","affiliation":[{"name":"Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Hruba","sequence":"additional","affiliation":[{"name":"Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Kollar","sequence":"additional","affiliation":[{"name":"Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Krejci","sequence":"additional","affiliation":[{"name":"3rd Department of Internal Medicine\u2014Nephrology, Rheumatology and Endocrinology, Teaching Hospital Olomouc, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Safranek","sequence":"additional","affiliation":[{"name":"Hemodialysis Centre, Teaching Hospital Hradec Kralove, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sona","family":"Stepankova","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular and Transplantation Surgery, Brno, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarmila","family":"Dedochova","sequence":"additional","affiliation":[{"name":"Department of Medicine, Teaching Hospital Ostrava, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Machova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, Teaching Hospital Pilsen, Czech Republic."},{"name":"Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Zieg","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janka","family":"Slatinska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Pokorna","sequence":"additional","affiliation":[{"name":"Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Viklicky","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."},{"name":"Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."},{"name":"Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"R1-20240805","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","article-title":"De novo thrombotic microangiopathy after kidney transplantation.","volume":"32","author":"Garg","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"key":"R2-20240805","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.transproceed.2012.07.039","article-title":"De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival.","volume":"44","author":"Caires","year":"2012","journal-title":"Transplant Proc"},{"key":"R3-20240805","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States.","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R4-20240805","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1046\/j.1523-1755.1999.00492.x","article-title":"Cyclosporine-associated thrombotic microangiopathy in renal allografts.","volume":"55","author":"Zarifian","year":"1999","journal-title":"Kidney Int"},{"key":"R5-20240805","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/j.1600-6143.2010.03178.x","article-title":"De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection.","volume":"10","author":"Satoskar","year":"2010","journal-title":"Am J Transplant"},{"key":"R6-20240805","doi-asserted-by":"crossref","first-page":"e0227445","DOI":"10.1371\/journal.pone.0227445","article-title":"Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes.","volume":"15","author":"Teixeira","year":"2020","journal-title":"PLoS One"},{"key":"R7-20240805","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1432-2277.2006.00354.x","article-title":"Thrombotic microangiopathy after kidney transplantation.","volume":"19","author":"Ponticelli","year":"2006","journal-title":"Transpl Int"},{"key":"R8-20240805","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection.","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"R9-20240805","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fmed.2017.00066","article-title":"Complement in kidney transplantation.","volume":"4","author":"Cernoch","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"R10-20240805","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy.","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"R11-20240805","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/cei.12124","article-title":"The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome.","volume":"173","author":"Gomez","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"R12-20240805","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1006\/mvre.1994.1030","article-title":"Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.","volume":"47","author":"Louise","year":"1994","journal-title":"Microvasc Res"},{"key":"R13-20240805","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1073\/pnas.87.10.3982","article-title":"Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid\/polyanion binding site on factor H.","volume":"87","author":"Meri","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-20240805","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jcla.20310","article-title":"Binding of anti-HLA class I antibody to endothelial cells produce an inflammatory cytokine secretory pattern.","volume":"23","author":"Reyes-Vargas","year":"2009","journal-title":"J Clin Lab Anal"},{"key":"R15-20240805","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00007890-199707270-00002","article-title":"Cellular and molecular predictors of chronic renal dysfunction after initial ischemia\/reperfusion injury of a single kidney.","volume":"64","author":"Azuma","year":"1997","journal-title":"Transplantation"},{"key":"R16-20240805","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/ndt\/gft488","article-title":"Ischaemia-reperfusion injury: a major protagonist in kidney transplantation.","volume":"29","author":"Ponticelli","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R17-20240805","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/TP.0b013e318291a298","article-title":"Glomerular mRNA expression of prothrombotic and antithrombotic factors in renal transplants with thrombotic microangiopathy.","volume":"95","author":"Agustian","year":"2013","journal-title":"Transplantation"},{"key":"R18-20240805","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/j.1600-6143.2009.02761.x","article-title":"Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining.","volume":"9","author":"Sis","year":"2009","journal-title":"Am J Transplant"},{"key":"R19-20240805","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1600-6143.2010.03201.x","article-title":"NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection.","volume":"10","author":"Hidalgo","year":"2010","journal-title":"Am J Transplant"},{"key":"R20-20240805","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/TP.0b013e31827e6b45","article-title":"Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis.","volume":"95","author":"Drachenberg","year":"2013","journal-title":"Transplantation"},{"key":"R21-20240805","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1681\/ASN.2014111064","article-title":"Reassessing the significance of intimal arteritis in kidney transplant biopsy specimens.","volume":"26","author":"Salazar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R22-20240805","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1042\/CS20180745","article-title":"Early isolated V-lesion may not truly represent rejection of the kidney allograft.","volume":"132","author":"Wohlfahrtova","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"R23-20240805","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ctr.12645","article-title":"The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy.","volume":"30","author":"Wu","year":"2016","journal-title":"Clin Transplant"},{"key":"R24-20240805","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0272-6386(96)90468-0","article-title":"Cyclosporine-associated thrombotic microangiopathy\/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation.","volume":"28","author":"Young","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"R25-20240805","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R26-20240805","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1681\/ASN.2008070715","article-title":"\u201cNature versus nurture\u201d study of deceased-donor pairs in kidney transplantation.","volume":"20","author":"Louvar","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R27-20240805","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1432-2277.2012.01517.x","article-title":"Concordance of outcomes of pairs of kidneys transplanted into different recipients.","volume":"25","author":"Traynor","year":"2012","journal-title":"Transpl Int"},{"key":"R28-20240805","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","article-title":"Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.","volume":"32","author":"Westra","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"R29-20240805","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation.","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"R30-20240805","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/ndt\/gfy316","article-title":"A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.","volume":"34","author":"Michielsen","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"R31-20240805","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1111\/j.1600-6143.2011.03741.x","article-title":"Impact of cold ischemia time on graft survival among ECD transplant recipients: a paired kidney analysis.","volume":"11","author":"Kayler","year":"2011","journal-title":"Am J Transplant"},{"key":"R32-20240805","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1097\/01.ASN.0000095250.92361.D5","article-title":"Long-term graft survival with neoral and tacrolimus: a paired kidney analysis.","volume":"14","author":"Kaplan","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R33-20240805","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/TP.0b013e318209f22b","article-title":"Recipient risk factors associated with delayed graft function: a paired kidney analysis.","volume":"91","author":"Doshi","year":"2011","journal-title":"Transplantation"},{"key":"R34-20240805","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantion Society Working Group.","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:06:38Z","timestamp":1722834398000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001239","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}